Determining the effect of Ivermectin administration on one-month death of patients with Covid-19
Clinical trial has acontrol group with parallel groups, this study was open label due to the lack of placebo , so there is no point in being blind.
Settings and conduct
Among patients referred to Emam Reza hospital, 80 patients were selected for study whose diagnosis is confirmed by inclusion criteria.
These patients were randomly divided into two groups with equal numbers.
In control group, patients receive all available treatments for Covid-19 according to the latest treatment protocol , and in case group ,in addition to similar treatments in the control group, patients are prescribed Ivermectin.with dose: 200 microgram per kilogram , in one dose up to two days .
Participants/Inclusion and exclusion criteria
Patients with Covid-19 whose diagnosis is confirmed by :
Physicians clinical diagnosis with patients clinical symptoms.
O2 saturation less than 93%
laboratory parameters(ESR,CRP,FERRITTIN,CBC and lymphocyte count ,D-dimer )
Positive Real time PCR test for SARS-CoV-19
Age between 16-75
Pregnancy and breast feeding
Concomitant use of Warfarin
over 75 years
In addition to similar treatments in the control group, patients are prescribed Ivermectin with dose 200 microgram per kilogram , up to two days in a row.
In control group, patients receive all available treatments for Covid-19 according to the latest protocol .
Main outcome variables
hospital stay ,severity of disease is measured by physician, improvement of laboratory parameters(ESR,CRP,FERRITTIN,CBC and lymphocyte count ,D-dimer ) , improvement of O2 saturation, need for mecanical ventilation.